文献速递贫血与红细胞疾病

羟基脲无致突变效应支持扩大其用于镰状细胞贫血治疗

Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia.
PubMed 文献 · Br J Haematol · 2021-02-11

本文综述了羟基脲治疗镰状细胞贫血(SCA)的遗传毒性与致癌潜能数据。基因毒性结果明确显示羟基脲不直接结合DNA且无致突变性,其遗传毒性仅限于特定细胞类型中超过高剂量和时间阈值时发生的间接断裂剂效应。鉴于该药无致突变活性且缺乏令人信服的致癌潜能,作者建议修改药品标签并扩大处方以增加药物可及性和利用率。

要点

  • 羟基脲不直接结合DNA,无致突变性。
  • 遗传毒性仅限于特定细胞类型中高剂量和时间阈值以上的间接断裂剂效应。
  • 羟基脲治疗SCA的致癌风险极小,应修改标签并扩大处方。

核心结论

  • 羟基脲无致突变活性,与缺乏令人信服的致癌潜能一致,治疗SCA的致癌风险极小。

研究设计与样本

  • 综述:汇总临床前与临床研究中羟基脲相关数据,讨论遗传毒性的实验室测量与致癌潜能。

主要发现

  • 羟基脲不直接结合DNA且无致突变性。
  • 其遗传毒性效应仅限于特定细胞类型中超过高剂量和时间阈值时发生的间接断裂剂效应。

临床怎么用

  • 当前药品标签应相应修改,处方实践应扩大以允许更好可及性和增加该高效药物的利用。

局限性

  • 长期存在的诱变和潜在致癌风险担忧主要基于过时的实验模型和骨髓增殖性肿瘤的治疗经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hydroxyurea (hydroxycarbamide) is approved for treating both children and adults with sickle cell anaemia (SCA). Fetal haemoglobin (HbF) induction is the primary treatment response, along with improved anaemia, reduced haemolysis, myelosuppression and decreased endothelial inflammation. Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. Despite these recognised benefits, long-standing concerns regarding the risks of mutagenic and potentially carcinogenic drug exposure have hampered efforts for broad hydroxyurea use in SCA, although these are based largely on outdated experimental models and treatment experiences with myeloproliferative neoplasms. Consequently, many patients with SCA are not receiving this highly effective disease-modifying therapy. In this review, we describe the concept of genotoxicity and its laboratory measurements, summarise hydroxyurea-associated data from both preclinical and clinical studies, and discuss carcinogenic potential. The genotoxicity results clearly demonstrate that hydroxyurea does not directly bind DNA and is not mutagenic. Rather, its genotoxic effects are limited to indirect clastogenicity occurring in select cell types, and only when high dose and time thresholds are exceeded. This absence of mutagenic activity is consistent with the observed lack of any compelling carcinogenic potential. Since hydroxyurea therapy for SCA carries minimal carcinogenic risks, the current drug labelling should be modified accordingly, and prescribing practices should be broadened to allow better access and increased utilisation of this highly effective drug.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ware RE, Dertinger SD. Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. Br J Haematol. 2021. PMID: 33570176. doi:10.1111/bjh.17323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。